Key result
Malignancy and cancer therapies are associated with clinical thrombosis, representing a significant complication that requires specialized approaches to diagnosis and treatment.
This review summarizes the epidemiology, pathogenesis, diagnosis, and treatment of thromboembolic complications in cancer patients.
Supports vigilant thrombosis management in cancer patients; reinforces consensus via updated evidence synthesis.
The association between malignancy and clinical thrombosis has been recognized for nearly 140 years. The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Sutherland et al. (2002) studied this question. Malignancy and cancer therapies are associated with clinical thrombosis, representing a significant complication that requires specialized approaches to diagnosis and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: